RT Journal Article
SR Electronic
T1 Rapid implementation of real-time SARS-CoV-2 sequencing to investigate healthcare-associated COVID-19 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.08.20095687
DO 10.1101/2020.05.08.20095687
A1 Luke W. Meredith
A1 William L. Hamilton
A1 Ben Warne
A1 Charlotte J. Houldcroft
A1 Myra Hosmillo
A1 Aminu S. Jahun
A1 Martin D. Curran
A1 Surendra Parmar
A1 Laura G. Caller
A1 Sarah L. Caddy
A1 Fahad A. Khokhar
A1 Anna Yakovleva
A1 Grant Hall
A1 Theresa Feltwell
A1 Sally Forrest
A1 Sushmita Sridhar
A1 Michael P. Weekes
A1 Stephen Baker
A1 Nicholas Brown
A1 Elinor Moore
A1 Ashley Popay
A1 Iain Roddick
A1 Mark Reacher
A1 Theodore Gouliouris
A1 Sharon J. Peacock
A1 Gordon Dougan
A1 M. Estée Török
A1 Ian Goodfellow
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.08.20095687.abstract
AB Background The burden and impact of healthcare-associated COVID-19 infections is unknown. We aimed to examine the utility of rapid sequencing of SARS-CoV-2 combined with detailed epidemiological analysis to investigate healthcare-associated COVID-19 infections and to inform infection control measures.Methods We set up rapid viral sequencing of SARS-CoV-2 from PCR-positive diagnostic samples using nanopore sequencing, enabling sample-to-sequence in less than 24 hours. We established a rapid review and reporting system with integration of genomic and epidemiological data to investigate suspected cases of healthcare-associated COVID-19.Results Between 13 March and 24 April 2020 we collected clinical data and samples from 5191 COVID-19 patients in the East of England. We sequenced 1000 samples, producing 747 complete viral genomes. We conducted combined epidemiological and genomic analysis of 299 patients at our hospital and identified 26 genomic clusters involving 114 patients. 66 cases (57.9%) had a strong epidemiological link and 15 cases (13.2%) had a plausible epidemiological link. These results were fed back to clinical, infection control and hospital management teams, resulting in infection control interventions and informing patient safety reporting.Conclusions We established real-time genomic surveillance of SARS-CoV-2 in a UK hospital and demonstrated the benefit of combined genomic and epidemiological analysis for the investigation of healthcare-associated COVID-19 infections. This approach enabled us to detect cryptic transmission events and identify opportunities to target infection control interventions to reduce further healthcare-associated infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded COG-UK, which is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. It was also supported by the Wellcome Trust (Senior Fellowship 207498/Z/17/Z and ARTIC Network Collaborative Award 206298/B/17/Z to IG, Collaborative Award 204870/Z/16/Z supporting CJH, Senior Research Fellowship to SGB 215515/Z/19/Z, Senior Clinical Research Fellowship 108070/Z/15/Z to MPW), the Academy of Medical Sciences and the Health Foundation (Clinician Scientist Fellowship to MET), and the National Institute for Health Research Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust (BW, GD, MET). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequence data from this manuscript are available from GISAD https://www.gisaid.org/ https://www.gisaid.org/